TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14643940

Group type: EXPERIMENTAL
Intervention: 12-Step counseling condition
Number of subjects: 252

Group type: COMPARATOR
Intervention: Cognitive-behavioral counseling condition
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Partial hospitalization setting
Number of subjects: 252

Group type: COMPARATOR
Intervention: Standard outpatient setting
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Self-help affiliation
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: High-severity patients
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Low-severity patients
Number of subjects: 252
Study: 11113718

Group type: EXPERIMENTAL
Intervention: Atenolol (maintenance dose 89±11 mg/day, range 50-100 mg/day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 100
Study: 9352289

Group type: EXPERIMENTAL
Intervention: Executive control function (measured by EXIT25 and MMSE)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Discriminant model based on EXIT25 and MMSE scores
Number of subjects: 105

Group type: COMPARATOR
Intervention: Probable Alzheimer's disease patients
Number of subjects: 105

Group type: COMPARATOR
Intervention: Institutionalized elderly retirees
Number of subjects: 105

Group type: COMPARATOR
Intervention: Noninstitutionalized retirees
Number of subjects: 105
Study: 8474401

Group type: EXPERIMENTAL
Intervention: Amitriptyline oxide (60 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Trimipramine (50 mg)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amitriptyline oxide and trimipramine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Adverse effects assessment
Number of subjects: 24
Study: 3776446

Group type: COMPARATOR
Intervention: Intramuscular oxycodone on request following an intraoperative intercostal block (Group C)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Intercostal blocks with 0.5% bupivacaine (Group IC)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epidural bupivacaine as a continuous infusion of 0.25% bupivacaine (Group EB)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epidural morphine 4 mg injected prior to surgery and on the first postoperative morning (Group EM4)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Epidural morphine 6 mg injected prior to surgery and on the first postoperative morning (Group EM6)
Number of subjects: 51
Study: 29529169

Group type: EXPERIMENTAL
Intervention: SOC + AAP (abiraterone acetate 1000 mg + prednisolone 5 mg daily)
Number of subjects: 566

Group type: COMPARATOR
Intervention: SOC + DocP (docetaxel 75 mg/m2 3-weekly x 6 + prednisolone 10 mg daily)
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: SOC + AAP
Number of subjects: 566

Group type: COMPARATOR
Intervention: SOC + DocP
Number of subjects: 566
Study: 27993759

Group type: EXPERIMENTAL
Intervention: app+counseling
Number of subjects: 833

Group type: COMPARATOR
Intervention: counseling only
Number of subjects: 833
Study: 24797189

Group type: EXPERIMENTAL
Intervention: Cognitive-Functional (Cog-Fun) intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 19
Study: 23190359

Group type: EXPERIMENTAL
Intervention: Progressive resistance training (PRT) with creatine and protein supplementation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (PLA) group undergoing identical PRT protocol with placebo supplementation
Number of subjects: 30
Study: 19875232

Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation (SCS)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Pain Clinic treatment
Number of subjects: 158

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 158
Study: 18160741

Group type: EXPERIMENTAL
Intervention: Gonadotropin-releasing hormone antagonist plus testosterone administration for 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Progestogen treatment
Number of subjects: 0
Study: 16177164

Group type: EXPERIMENTAL
Intervention: Nitrous oxide treatment (NO); N2O and EMLA
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional treatment (CO); cutaneous application of EMLA
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Nitrous oxide treatment (NO)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nitrous oxide treatment (NO) and Conventional treatment (CO)
Number of subjects: 70
Study: 12709682

Group type: EXPERIMENTAL
Intervention: Diltiazem (1 g/kg/min during CPB)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 30
Study: 11128561

Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg/day i.m. for a minimum of 4 months
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Teicoplanin 200 mg/day i.m. (reduced dose for 2 patients)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Teicoplanin treatment
Number of subjects: 76
Study: 8793451

Group type: EXPERIMENTAL
Intervention: 0.3 ppm NO2 in ambient air
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 0.6 ppm NO2 in ambient air
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ambient air + combustion by-products + 0.3 ppm NO2
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Ambient air + combustion by-products + 0.6 ppm NO2
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ambient air (control)
Number of subjects: 20
Study: 1621789

Group type: EXPERIMENTAL
Intervention: 2% epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.1% dipivefrin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% epinephrine with nasolacrimal occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% epinephrine with and without nasolacrimal occlusion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.05% dipivefrin every 12 hours
Number of subjects: 0
Study: 6388897

Group type: EXPERIMENTAL
Intervention: Neomycin (2 g/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Neomycin plus Niacin (3 g/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined treatment with Neomycin plus Niacin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Diet-only therapy
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Combined regimen compliance
Number of subjects: 25
Study: 31402718

Group type: EXPERIMENTAL
Intervention: Naproxen sodium (NAPSO) 440 mg
Number of subjects: 385

Group type: COMPARATOR
Intervention: Ibuprofen (IBU) 400 mg
Number of subjects: 385

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 385
Study: 27553214

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80mg every 2 weeks (IXEQ2W)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80mg every 4 weeks (IXEQ4W)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Adalimumab 40mg every 2 weeks
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Ixekizumab (both regimens)
Number of subjects: 417
Study: 26573022

Group type: EXPERIMENTAL
Intervention: Ceftobiprole 500 mg, administered by 2-hour intravenous infusion every 8 hours.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ceftazidime/linezolid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ceftobiprole
Number of subjects: 0
Study: 27129122

Group type: EXPERIMENTAL
Intervention: PRTX-100 (0.15, 0.45, 0.90, or 1.50 µg/kg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PRTX-100
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22959335

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning (4 doses of 2 Gy total-body irradiation and 150 mg/m² fludarabine)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard conditioning (6 doses of 2 Gy total-body irradiation and 120 mg/kg cyclophosphamide)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Reduced-intensity conditioning
Number of subjects: 195

Group type: COMPARATOR
Intervention: Standard conditioning
Number of subjects: 195
Study: 20214336

Group type: EXPERIMENTAL
Intervention: Xiaomi granules (XMG)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Anticandine (Control)
Number of subjects: 40
Study: 18156036

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors (rofecoxib, celecoxib, sulindac, meloxicam, indometacin) with low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors with low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors (celecoxib, rofecoxib) with low-dose aspirin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: COX-2 inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-selective NSAIDs with low-dose aspirin
Number of subjects: 0
Study: 15074088

Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpu Decoction (MBHD) in treated group A
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Modified Banxia Houpu Decoction (MBHD) in treated group B
Number of subjects: 187

Group type: COMPARATOR
Intervention: Imitate preparation in control group
Number of subjects: 187
Study: 16098301

Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography with real-time low mechanical index perfusion imaging (using intravenous Optison)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Dobutamine stress echocardiography without real-time perfusion imaging (high mechanical index harmonic imaging)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Real-time perfusion imaging
Number of subjects: 27
Study: 10332666

Group type: EXPERIMENTAL
Intervention: Diet combined with aerobic exercise (DA)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Diet combined with resistance exercise (DR)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Diet alone (DO)
Number of subjects: 29
Study: 8743516

Group type: EXPERIMENTAL
Intervention: Ca antagonists
Number of subjects: 22

Group type: COMPARATOR
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 22
Study: 1656826

Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet at a dose of 60 mg/kg body weight three times a day for 3 weeks followed by 90 mg/kg once a day (treatment group)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No therapy (delayed treatment, control group)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Foscarnet treatment
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 24
Study: 7042113

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4524

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Loss of Q waves
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Persistent Q waves in a single infarct location
Number of subjects: 4524

Group type: EXPERIMENTAL
Intervention: Multiple electrocardiographic infarct locations
Number of subjects: 4524
Study: 30951586

Group type: EXPERIMENTAL
Intervention: Home-based behavioral skills treatment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Contingency management with voucher-based reinforcement
Number of subjects: 181

Group type: COMPARATOR
Intervention: Continued skills without contingency management
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Continued skills for younger adolescents
Number of subjects: 181
Study: 29261566

Group type: EXPERIMENTAL
Intervention: Intubation-related cardiac arrest
Number of subjects: 1847
Study: 26768099

Group type: EXPERIMENTAL
Intervention: Axillary node sampling (ANS)
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Axillary node sampling (ANS) + axillary radiotherapy (AXRT)
Number of subjects: 799
Study: 25480930

Group type: EXPERIMENTAL
Intervention: Moderate Intensity Continuous Exercise (MICE) at 50% HRR for 25 min
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: High Intensity Intermittent Exercise (HIIE) at 100% HRR for 30s followed by 30s rest for 25 min
Number of subjects: 34

Group type: COMPARATOR
Intervention: Non-exercise group
Number of subjects: 34
Study: 22648790

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 4 Hz (200 mJ, 12 mm, 20 s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 6 Hz (200 mJ, 12 mm, 20 s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Er:YAG laser at 10 Hz (200 mJ, 12 mm, 20 s)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All frequencies (4, 6, 10 Hz) on sound dentin
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All frequencies (4, 6, 10 Hz) on carious dentin
Number of subjects: 60
Study: 20810101

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Maintenance antidepressants (mADM)
Number of subjects: 123
Study: 18253048

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-Eicosapentaenoic acid (non-EPA)
Number of subjects: 100
Study: 15757007

Group type: EXPERIMENTAL
Intervention: Inpatient relapse prevention (RP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (untreated prison control groups)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient relapse prevention (RP) program (treatment goal met)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inpatient relapse prevention (RP) program (treatment goal not met)
Number of subjects: 0
Study: 11882751

Group type: EXPERIMENTAL
Intervention: Laparoscopic repair
Number of subjects: 121

Group type: COMPARATOR
Intervention: Open repair
Number of subjects: 121
Study: 10048703

Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 0
Study: 7541435

Group type: EXPERIMENTAL
Intervention: Propacetamol (2 g every 6 hr)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 31299655

Group type: EXPERIMENTAL
Intervention: Tiopronin (3 g daily for up to 14 days after aSAH)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 28237759

Group type: EXPERIMENTAL
Intervention: Center for Epidemiological Studies – Depression Scale (CES-D)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: CES-D
Number of subjects: 91
Study: 25904586

Group type: EXPERIMENTAL
Intervention: Particle-filtered air (PM2.5 levels of 3 µg/m(3))
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham-filtered air (PM2.5 levels of 24 µg/m(3))
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Exposure to PM from urban street air
Number of subjects: 60
Study: 23552179

Group type: EXPERIMENTAL
Intervention: Saline infusion
Number of subjects: 195

Group type: COMPARATOR
Intervention: Bicarbonate infusion
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Saline infusion (in subset with baseline creatinine clearance < 60 mL/min)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Bicarbonate infusion (in subset with baseline creatinine clearance < 60 mL/min)
Number of subjects: 195
Study: 22037701

Group type: EXPERIMENTAL
Intervention: Electrode surface area 254 mm(2) with 30 s sampling time
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electrode surface area 474 mm(2) with 30 s sampling time
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electrode surface area 254 mm(2) with 7.5 s sampling time
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Electrode surface area 474 mm(2) with 7.5 s sampling time
Number of subjects: 120
Study: 17265545

Group type: EXPERIMENTAL
Intervention: Tai Chi training (18 weeks, 45 min, twice a week)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 49
Study: 16100235

Group type: EXPERIMENTAL
Intervention: GIK (glucose-insulin-potassium) treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: GIK treatment
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 21
Study: 11900099

Group type: EXPERIMENTAL
Intervention: Participants cued to forget the 1st of 2 studied lists before studying the 2nd
Number of subjects: 0

Group type: COMPARATOR
Intervention: Providing some studied words as cues during recall
Number of subjects: 0
Study: 10521999

Group type: EXPERIMENTAL
Intervention: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus ampicillin/salbactum (1.5 gm i.v. loading then 750 mg q 9 am, 3 pm, & 9 pm)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus metronidazole and erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 3-day intravenous omeprazole (80 mg loading then 40 mg q 9 am & 9 pm) plus erythromycin (both 500 mg i.v. q 9 am, 3 pm, & 9 pm)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Oral dual therapy (omeprazole 20 mg and amoxycillin 1 g bid x 2 weeks)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: 3-day intravenous regimens (Groups 1-3)
Number of subjects: 138
Study: 7491890

Group type: EXPERIMENTAL
Intervention: 130 g dry lentils/d
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 9
Study: 1791775

Group type: EXPERIMENTAL
Intervention: 10 mg dydrogesterone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 20 mg dydrogesterone
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (50 mg oestradiol implant)
Number of subjects: 30
Study: 6754212

Group type: EXPERIMENTAL
Intervention: Levonantradol 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levonantradol 0.75 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorpromazine 26 mg
Number of subjects: 0
Study: 31550775

Group type: EXPERIMENTAL
Intervention: HGSC-SET I (25%-50%)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: HGSC-SET II (>50%)
Number of subjects: 408

Group type: COMPARATOR
Intervention: HGSC-classic group (<25%)
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: HGSC-SET I
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: HGSC-SET II
Number of subjects: 408
Study: 29975689

Group type: EXPERIMENTAL
Intervention: Cash transfers for school attendance
Number of subjects: 2533

Group type: COMPARATOR
Intervention: Control group (no cash transfers)
Number of subjects: 2533
Study: 25075979

Group type: EXPERIMENTAL
Intervention: BIG device
Number of subjects: 52

Group type: COMPARATOR
Intervention: EZ-IO device
Number of subjects: 52
Study: 25074283

Group type: EXPERIMENTAL
Intervention: CWI-10 min × 20 °C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CWI-30 min × 20 °C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CWI-10 min × 10 °C
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: CWI-30 min × 10 °C
Number of subjects: 8

Group type: COMPARATOR
Intervention: Passive rest (Control)
Number of subjects: 8
Study: 22995043

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 485)
Number of subjects: 700

Group type: COMPARATOR
Intervention: Control group (n = 215)
Number of subjects: 700
Study: 19732445

Group type: COMPARATOR
Intervention: Placebo group receiving 500 mg medicinal starch daily
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: GTP group receiving 500 mg of GTP per day
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Placebo+TC group receiving both placebo treatment and TC training (60‐minute group exercise, 3 times per week)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: GTP+TC group receiving both GTP and TC training for 24 weeks
Number of subjects: 140
Study: 17647187

Group type: EXPERIMENTAL
Intervention: Health education intervention based on the Health Belief Model (HBM) - two sessions of one hour each
Number of subjects: 206

Group type: COMPARATOR
Intervention: Traditional didactic health education curriculum on osteoporosis
Number of subjects: 206

Group type: COMPARATOR
Intervention: No specific educational program for osteoporosis prevention
Number of subjects: 206
Study: 15607599

Group type: EXPERIMENTAL
Intervention: Moderate systemic hypothermia (33 degrees C) for 48 hours
Number of subjects: 65

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C) for 48 hours
Number of subjects: 65
Study: 11856113

Group type: EXPERIMENTAL
Intervention: Regular neourethral dilatation for 12 weeks (Group 1)
Number of subjects: 64

Group type: COMPARATOR
Intervention: No neourethral dilatation (Group 2)
Number of subjects: 64
Study: 10667742

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 183

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Low doses of risperidone or haloperidol (maximum, < or = 6 mg/day)
Number of subjects: 183
Study: 7790470

Group type: EXPERIMENTAL
Intervention: Enterotoxigenic E. coli (ETEC)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Enteropathogenic E. coli (EPEC)
Number of subjects: 1053

Group type: COMPARATOR
Intervention: Control group (children without diarrhea)
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Enteroinvasive E. coli
Number of subjects: 1053

Group type: EXPERIMENTAL
Intervention: Enteroaggregative and diffuse adherent E. coli
Number of subjects: 1053
Study: 2216994

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 67

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 67
Study: 25663

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg alone
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam 2 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam 4 mg + Atropine 0.4 mg + Hyoscine 0.4 mg
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lorazepam + Hyoscine
Number of subjects: 150
Study: 31003212

Group type: EXPERIMENTAL
Intervention: Post-aSAH syndrome group (33% of patients)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Recovery group
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Post-aSAH syndrome group
Number of subjects: 128
Study: 30106348

Group type: EXPERIMENTAL
Intervention: 24-hour metformin discontinuation
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 48-hour metformin discontinuation
Number of subjects: 90

Group type: COMPARATOR
Intervention: No metformin discontinuation (control)
Number of subjects: 90
Study: 26577455

Group type: EXPERIMENTAL
Intervention: 0.1 mm MAL cream
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.2 mm MAL cream
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 0.4 mm MAL cream
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 1.0 mm MAL cream
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Light-impermeable occlusion
Number of subjects: 16